Appl. Serial No. 10/646,256 Amendment dated August 19, 2004 Reply to Office Action mailed July 29, 2004

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5 (canceled)

6. (original) A compound of the formula:

$$R_1$$
 N
 R_2
 R_3

wherein

R1 is a halogenated phenyl;

R2 is bicyclo[2.2.1]heptane, cyclopropane or cyclohexane; and,

R3 is NH2, OH or 2-amino-3-phenylpropanamide.

- 7. (original) The compound of Claim 6, wherein R1 is 3,4-dichlorophenyl.
- 8. (original) The compound of Claim 6, wherein R1 is 3-chlorophenyl.
- 9. (original) The compound of Claim 6, wherein R3 is OH.
- 10. (original) The compound of Claim 6, wherein R3 is 2-amino-3-phenylpropanamide.

Appl. Serial No. 10/646,256 Amendment dated August 19, 2004 Reply to Office Action mailed July 29, 2004

- 11. (original) A pharmaceutical composition comprising a compound of Claim 6 or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.
- 12-31 (cancelled)
- 32. (currently amended): A method of treating colon cancer for inhibiting protein prenylation comprising administering to a mammal in need of such treatment a therapeutically effective amount of contacting an isoprenoid transferase with a compound of the formula:

$$R_1$$
 N
 R_2
 R_3

or a pharmaceutically-acceptable salt thereof, wherein

R1 is a halogenated phenyl;

R2 is bicyclo[2.2.1]heptane, cyclopropane or cyclohexane; and,

R3 is NH2, OH or 2-amino-3-phenylpropanamide.

- 33. (original) The method of Claim 32, wherein R1 is 3,4-dichlorophenyl.
- 34. (original) The method of Claim 32, wherein R1 is 3-chlorophenyl.
- 35. (original) The method of Claim 32, wherein R3 is OH.
- 36. (original) The method of Claim 32, wherein R3 is 2-amino-3-phenylpropanamide.
- 37. (cancelled)

Appl. Serial No. 10/646,256 Amendment dated August 19, 2004 Reply to Office Action mailed July 29, 2004

- 38. (cancelled)
- 39. (original) The method of Claim 32, wherein said compound inhibits farnesyl-protein transferase.
- 40. (original) The method of Claim 32, wherein said compound modulates geranylgeranyl-protein transferase Type I.
- 41. (original) The method of Claim 40, wherein said compound has an IC50 value of about 60nM or less.
- 42. (original) The method of Claim 32, wherein said compound modulates geranylgeranyl-protein transferase Type II.
- 43-62 (cancelled)